Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ProPhase pares costs, preps relaunches

This article was originally published in The Tan Sheet

Executive Summary

The OTC firm, formerly known as Quigley, discontinues a candy product line and shutters a contract manufacturing facility, reducing first-quarter operating costs and expenses 51 percent to $2.2 million. ProPhase Labs' net sales in the January-March period also dropped 50.4 percent to $2 million, but its year-over-year net loss was halved to $1.1 million. Sales took a hit as retailer orders of cold and flu products, such as ProPhase's Cold-EEZE zinc lozenges, were front-loaded in fourth quarter 2009, according to CEO Ted Karkus. He added May 17 ProPhase is entering "a wonderful new phase," with redesigned packaging, a new mint frost Cold-EEZE flavor and the planned reintroduction of a Kids-EEZE non-liquid product line (1"The Tan Sheet" May 10, 2010, In Brief)
Advertisement

Related Content

Cold-EEZE continues brand transformation
Quigley now ProPhase Labs
Advertisement
UsernamePublicRestriction

Register

PS104145

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel